[Effects of heparin and anticardiolipin antibodies positive serum from patients with recurrent pregnancy loss on proliferation of BeWo cells].
OBJECTIVE
To investigate the effects of anticardiolipin antibodies positive serum from patients with recurrent pregnancy loss on the proliferation of BeWo cells as well as the modulation of heparin on the growth of BeWo cell.


METHODS
Thirty patients with recurrent pregnancy loss whose anticardiolipin antibodies were positive and thirty healthy women with a history of term delivery were selected. Their sera were separately added to BeWo cell culture systems which contained either heparin or not. After 24 hours, the PCNA and 490 nm A value were detected by immunofluorescence and methyl thiazolyl tetrazolium (MTT), and the proliferation of BeWo cell was evaluated.


RESULTS
In the culture systems with heparin and normal serum, normal serum, heparin and serum with positive autoantibody, serum with positive autoantibody, the mean fluorescence gray scale values of PCNA were 34.8 +/- 3.1, 33.8 +/- 1.8, 33.4 +/- 2.2 and 25.1 +/- 2.3, the 490 nm A values were 0.0560 +/- 0.0033, 0.0535 +/- 0.0024, 0.0524 +/- 0.0027 and 0.0350 +/- 0.0040, respectively.


CONCLUSIONS
The serum with anticardiolipin antibodies from patients with recurrent pregnancy loss can influence the prospective potency of BeWo cell, inhibit cell proliferation in vitro. Through this direct effect on biological behaviour of the trophoblastic cell, it will lead to recurrent pregnancy loss, whereas heparin can increase the ratio of pregnancy by reversing such effects in those patients.
Liu
Zong-hua
ZH
Department of Obstetrics and Gynecology, Shandong Provincial Hospital, Shandong University, Jinan 250021, China.
Wang
Xie-tong
XT
Wang
Yan-yun
YY
Li
Yun
Y
Gao
Jin-yu
JY
Yu
Xiao-yan
XY
D000026:Abortion, Habitual / Q000097:blood* / Q000276:immunology; D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D003470:Culture Media / Q000737:chemistry / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000276:immunology; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D012189:Retrospective Studies; D044967:Serum / Q000737:chemistry / Q000276:immunology
D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D003470:Culture Media; D018809:Proliferating Cell Nuclear Antigen; D006493:Heparin